Efficacy of BAFF inhibition and B-cell depletion in non-obese diabetic mice as a spontaneous model for Sjögren's disease.
Fiche publication
Date publication
août 2024
Journal
RMD open
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DUMORTIER Hélène, Pr GOTTENBERG Jacques-Eric
Tous les auteurs :
Felten R, Foray AP, Schneider P, Marquet C, Pecquet C, Monneaux F, Dumortier H, Sibilia J, Valette F, Chatenoud L, Gottenberg JE
Lien Pubmed
Résumé
The therapeutic interest of targeting B-cell activating factor (BAFF) in Sjögren's disease (SjD) can be suspected from the results of two phase II clinical trials but has not been evaluated in an animal model of the disease. We aimed to evaluate the therapeutic efficacy of this strategy on dryness and salivary gland (SG) infiltrates in the NOD mouse model of SjD.
Mots clés
B-Lymphocytes, Sjogren's Syndrome, T-Lymphocytes
Référence
RMD Open. 2024 08 28;10(3):